Evaluation of Allergic Reactions Following Intravenous Infusion of Polyvalent Antivenom in Snakebite Patients
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: Antivenom is a gold-standard treatment for snakebite envenoming. However, adverse reactions to snake antivenom are common in many parts.
OBJECTIVE: The aim of this study was to evaluate the allergic reactions following intravenous administration of antivenom sera.
METHODS: This was retrospective study conducted on snakebites patients referred to the Rahimi Hospital in Khorramabad. The files of these patients were accessed for demographic data, snakebite-related data, treatment provided, clinical presentation and allergic reaction status as a result of antivenom treatment.
RESULTS: 141 cases were investigated, including 73.8% male and 26.2% female patients. The mean age of the patients was 38.1±17.1 years. Age group 30-39 years accounted for the highest number of snakebite cases (24.1%). A majority of victims (89.4%) were from rural areas. Most of the patients (51.8%) were bitten in the spring and highest number of snakebite were reported in May (39.1%). The most common site of snakebite was lower extremities (50.4%) and upper extremities (44.7%). Among clinical feature of snakebite, pain was the most prevalent in 135 cases (95.7%) followed by swelling (83.7%). The mean antivenom vials used were 6.5±3.7 vials. Allergic reactions occurred in 6 patients (4.26%); reactions were mild in 5 patients and severe in 1 patient. The commonest presentation was maculopapular rash (1.4%) and the least common were headache (0.71%), nausea (0.71%), fever (0.71) and hypotension (0.71%).
CONCLUSION: Snakebite is one of the significant life-threatening environmental events. Immediate antivenom treatment can reduce mortality however, patients should be carefully monitored for adverse allergic reactions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Anti-inflammatory & anti-allergy agents in medicinal chemistry - 20(2021), 4 vom: 28., Seite 367-372 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mahmoudi, Ghafar-Ali [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allergic reaction |
|---|
| Anmerkungen: |
Date Completed 17.01.2022 Date Revised 17.01.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871523020666210204143756 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM321234332 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM321234332 | ||
| 003 | DE-627 | ||
| 005 | 20231225175355.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871523020666210204143756 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1070.xml |
| 035 | |a (DE-627)NLM321234332 | ||
| 035 | |a (NLM)33563188 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mahmoudi, Ghafar-Ali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of Allergic Reactions Following Intravenous Infusion of Polyvalent Antivenom in Snakebite Patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2022 | ||
| 500 | |a Date Revised 17.01.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: Antivenom is a gold-standard treatment for snakebite envenoming. However, adverse reactions to snake antivenom are common in many parts | ||
| 520 | |a OBJECTIVE: The aim of this study was to evaluate the allergic reactions following intravenous administration of antivenom sera | ||
| 520 | |a METHODS: This was retrospective study conducted on snakebites patients referred to the Rahimi Hospital in Khorramabad. The files of these patients were accessed for demographic data, snakebite-related data, treatment provided, clinical presentation and allergic reaction status as a result of antivenom treatment | ||
| 520 | |a RESULTS: 141 cases were investigated, including 73.8% male and 26.2% female patients. The mean age of the patients was 38.1±17.1 years. Age group 30-39 years accounted for the highest number of snakebite cases (24.1%). A majority of victims (89.4%) were from rural areas. Most of the patients (51.8%) were bitten in the spring and highest number of snakebite were reported in May (39.1%). The most common site of snakebite was lower extremities (50.4%) and upper extremities (44.7%). Among clinical feature of snakebite, pain was the most prevalent in 135 cases (95.7%) followed by swelling (83.7%). The mean antivenom vials used were 6.5±3.7 vials. Allergic reactions occurred in 6 patients (4.26%); reactions were mild in 5 patients and severe in 1 patient. The commonest presentation was maculopapular rash (1.4%) and the least common were headache (0.71%), nausea (0.71%), fever (0.71) and hypotension (0.71%) | ||
| 520 | |a CONCLUSION: Snakebite is one of the significant life-threatening environmental events. Immediate antivenom treatment can reduce mortality however, patients should be carefully monitored for adverse allergic reactions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Snakebites | |
| 650 | 4 | |a allergic reaction | |
| 650 | 4 | |a antivenom | |
| 650 | 4 | |a life-threatening. | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a venomous | |
| 650 | 7 | |a Antivenins |2 NLM | |
| 700 | 1 | |a Ahadi, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Fouladvand, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Rezaei, Bareza |e verfasserin |4 aut | |
| 700 | 1 | |a Bodagh, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Astaraki, Peyman |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-inflammatory & anti-allergy agents in medicinal chemistry |d 2009 |g 20(2021), 4 vom: 28., Seite 367-372 |w (DE-627)NLM194511715 |x 1875-614X |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2021 |g number:4 |g day:28 |g pages:367-372 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871523020666210204143756 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2021 |e 4 |b 28 |h 367-372 | ||